Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Mol Cancer Ther. 2019 Aug 14;18(11):2063–2073. doi: 10.1158/1535-7163.MCT-19-0520

Figure 2: Clonogenic survival of IBC cell lines decreases with olaparib treatment.

Figure 2:

Olaparib treatment results in a dose-dependent reduction in survival fraction of SUM-190 (A), MDA-IBC-3 (C), and SUM-149 (E) cell lines. Representative data from single experiments are shown for each cell line. The surviving fraction of cells after 6 Gy (B, D, F) was calculated as the mean of three independent experiments and depicted ± SEM for each cell line. (p < 0.05 = *, p < 0.01 = **)